Patents Assigned to Dana-Farber Cancer Institute
  • Publication number: 20240197678
    Abstract: Disclosed are compounds which inhibit Pin1 activity, methods of making the compounds, pharmaceutical compositions containing the compounds, and methods of using the compounds to treat diseases or disorders characterized or mediated by dysregulated Pin1 activity.
    Type: Application
    Filed: March 18, 2022
    Publication date: June 20, 2024
    Applicants: DANA-FARBER CANCER INSTITUTE, INC., YEDA RESEARCH AND DEVLOPMENT CO. LTD.
    Inventors: Inchul You, Nathanael S. Gray, Tinghu Zhang, Sirano Dhe-Paganon, Nir London, Christian Dubiella
  • Publication number: 20240190942
    Abstract: Methods and compositions for cancer immunotherapy are provided. The methods involve the use of a chimeric molecule (e.g., fusion protein) comprising a dimeric NKG2D portion and an Fc portion, which binds one or more NKG2D ligands. In some embodiments, the molecule further comprises a drug moiety (e.g., an IL15/Ra moiety). The methods disclosed herein are useful for the treatment of cancer that is associated with abnormal expression of one or more NKG2D ligands.
    Type: Application
    Filed: November 10, 2023
    Publication date: June 13, 2024
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Glenn Dranoff, Ryan Sullivan, Matthew Vanneman
  • Patent number: 12005073
    Abstract: The present invention is based, in part, on methods for modulating regulatory T cells, regulatory B cells, and immune responses using modulators of the APRIL-TACI interaction.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: June 11, 2024
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Kenneth C. Anderson, Yu-Tzu Tai
  • Patent number: 11998593
    Abstract: The present invention comprises compositions, methods, and devices for enhancing an endogenous immune response against a cancer. Devices and methods provide therapeutic immunity to subjects against cancer.
    Type: Grant
    Filed: May 18, 2020
    Date of Patent: June 4, 2024
    Assignees: President and Fellows of Harvard College, Dana-Farber Cancer Institute, Inc.
    Inventors: Omar Abdel-Rahman Ali, David J. Mooney, Glenn Dranoff
  • Patent number: 12000843
    Abstract: The invention features compositions and methods for the treatment and prevention of peroxisomal diseases (e.g., neonatal adrenoleukodystrophy and Zellweger syndrome), including in a subject selected as having increased levels of metallothionein polypeptides. The invention also provides compositions and methods for identifying a subject having a peroxisomal disease involving detecting metallothionein polypeptides or polynucleotides.
    Type: Grant
    Filed: January 16, 2018
    Date of Patent: June 4, 2024
    Assignees: Children's Medical Center Corporation, Ospedale San Raffaele S.R.L., Dana-Farber Cancer Institute, Inc., Fondazione Telethon
    Inventors: Alessandra Biffi, Eleonora Cavalca
  • Patent number: 11999729
    Abstract: Provided herein are compounds that interrupt the function of SALL4. Also described are pharmaceutical compositions and medical uses of these compounds.
    Type: Grant
    Filed: November 1, 2022
    Date of Patent: June 4, 2024
    Assignees: DANA-FARBER CANCER INSTITUTE, INC., THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Jun Qi, Anthony Varca, Li Chai
  • Publication number: 20240165259
    Abstract: Disclosed are compounds and pharmaceutically acceptable salts and stereoisomers thereof that are suitable for cellular labeling or the treatment of cancer. Also disclosed are pharmaceutical compositions containing same, and methods of making and using the compounds.
    Type: Application
    Filed: April 4, 2022
    Publication date: May 23, 2024
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Justin Kim, Dahye Kang
  • Publication number: 20240156800
    Abstract: The present invention relates to methods for treating a disease or disorder associated with EP300 dependency and elevated CRBN expression levels (e.g., cancer (e.g., neuroblastoma)).
    Type: Application
    Filed: March 8, 2022
    Publication date: May 16, 2024
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Jun Qi, Adam D. Durbin
  • Publication number: 20240158403
    Abstract: The present disclosure provides novel heteroaryl compounds of formula (IX). Such compounds are useful for the treatment of cancers.
    Type: Application
    Filed: January 24, 2024
    Publication date: May 16, 2024
    Applicants: Dana-Farber Cancer Institute, Inc., The Scripps Research Institute
    Inventors: Nathanael S. GRAY, Jianming ZHANG, Barun OKRAM, Xianming DENG, Jae Won CHANG, Amy WOJCIECHOWSKI
  • Patent number: 11981922
    Abstract: The present invention is generally directed to identify interacting cells in the tumor microenvironment and using the identified interactions to enhance anti-tumor immunity in cancer. Identified interactions can be modulated using therapeutic agents. Immune cells resistant to suppression can be used for adoptive cell transfer. The present invention is also generally directed to cell types and genes that are correlated to time of tumor growth and tumor size.
    Type: Grant
    Filed: October 5, 2020
    Date of Patent: May 14, 2024
    Assignees: DANA-FARBER CANCER INSTITUTE, INC., THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Meromit Singer, Aviv Regev, Orit Rozenblatt-Rosen, Davide Mangani, Ana Carrizosa Anderson, Vijay K. Kuchroo, Linglin Huang
  • Patent number: 11982674
    Abstract: In some embodiments, a mass spectrometry tag may comprise a linker region, a mass balance region, and a reporter region. The mass spectrometry tag may be configured to fragment in a mass spectrometer via an energy dependent process to produce multiple reporter molecules. For example, the reporter region of the tag may be configured to produce at least two reporter molecules via fragmentation. In some embodiments, one or more regions of the tag may comprise at least one heavy isotope. In some such embodiments, the ability to fragment into multiple reporter molecules as well as the placement and/or number of heavy isotope(s) allows the mass spectrometry tag to be distinguished from other similar mass spectrometry tags. In some such embodiments, the ability to distinguish between tags having the same or substantially similar total mass to charge ratio and reporter region mass may allow the system to have a greater multiplexing capacity than conventional systems.
    Type: Grant
    Filed: July 28, 2021
    Date of Patent: May 14, 2024
    Assignees: President and Fellows of Harvard College, Dana-Farber Cancer Institute, Inc.
    Inventors: Craig Braun, Wilhelm Haas, Steven P. Gygi, Gregory H. Bird, Loren D. Walensky, Martin Helmut Wuhr, Brian K. Erickson
  • Publication number: 20240150711
    Abstract: The disclosure provides methods of reprogramming polyclonal T cells to maintain long-term persistence. The disclosure further provides methods of treatment, such as adoptive T cell transfer therapies, that harness Tscms for development of tumor-reactive T cells. In some embodiments, the disclosure provides methods and compositions for positive modulation of the Tscm-producing phenotype, e.g., positive modulation of TCF7 expression. Positive modulation of TCF7 expression allows for maintenance of an increased T number of stem-like T cells capable of both self-renewal and generation of differentiated, cytolytic progeny.
    Type: Application
    Filed: March 1, 2022
    Publication date: May 9, 2024
    Applicants: Dana-Farber Cancer Institute, Inc., The General Hospital Corporation
    Inventors: Marc Schwartz, Nir Hacohen
  • Publication number: 20240142437
    Abstract: Presented are methods of assessing the teratogenicity of agents by measuring the degradation of SALL4, and related compounds with reduced teratogenicity. Provided herein is a method for assessing the teratogenicity of an agent comprising: contacting an agent with SALL4; and measuring levels of SALL4, wherein the agent is teratogenic if SALL4 levels are substantially reduced in the presence of the agent relative to in the absence of the agent.
    Type: Application
    Filed: September 22, 2023
    Publication date: May 2, 2024
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Eric S. Fischer, Katherine Donovan
  • Patent number: 11971411
    Abstract: The present invention provides methods for screening and diagnosing prostate cancer based on a correlation between cancer cell growth, cancer lethality or recurrence and the expression level of ZFP36 or NEDD9 and PTEN in conjunction with ZFP36. The disclosure also provides methods for screening and diagnosing prostate cancer based on a correlation between cancer lethality and the genotype of rs1910301 SNP. Also provided are methods for treating prostate cancer comprising providing a treatment or monitoring based on the expression level of ZFP36, the expression level of NEDD9, and the expression level of ZFP36 in conjunction with PTEN levels or the genotype of rs1910301 SNP.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: April 30, 2024
    Assignees: DANA-FARBER CANCER INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Curtis Huttenhower, Travis Gerke, Christopher Sweeney, Lorelei Mucci, Gwo-Sho Mary Lee, Daniela Bornigen, Xiaodong Wang, Svitlana Tyekucheva, Kristina Jordahl
  • Patent number: 11963966
    Abstract: Described herein are compositions and methods of using single-cell RNA-sequencing to identify treatment resistance in patients with ovarian cancer. Also, described herein are compositions and methods for treatment targeting resistance in patients with ovarian cancer.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: April 23, 2024
    Assignees: Dana-Farber Cancer Institute, Inc., The Broad Institute, Inc., Massachusetts Institute of Technology
    Inventors: Levi Garraway, Benjamin Izar, Aviv Regev, Orit Rozenblatt-Rosen, Asaf Rotem, Elizabeth Stover, Itay Tirosh
  • Publication number: 20240125787
    Abstract: Provided herein are STING and SPARCS genes as biomarkers for determining an effective therapy for treating cancer. Further provided are methods for treating cancer using said biomarkers.
    Type: Application
    Filed: December 5, 2023
    Publication date: April 18, 2024
    Applicants: Dana-Farber Cancer Institute, Inc., The Brigham and Women's Hospital, Inc.
    Inventors: David Barbie, Israel CaƱadas, Shunsuke Kitajima, Thanh Barbie
  • Patent number: 11957739
    Abstract: The present invention provides compositions and methods for treating cancers with reduced or absent CDH1 using a RHOA dominant negative polypeptide or biologically active fragment thereof, and/or a nucleic acid encoding a RHOA dominant negative polypeptide or biologically active fragment thereof.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: April 16, 2024
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Adam Bass, Haisheng Zhang
  • Patent number: 11957713
    Abstract: The present invention provides compositions and methods for the treatment or prevention of a neurological disease or disorder of the central nervous system (e.g., a storage disorder, lysosomal storage disorder, neurodegenerative disease, etc.) by reconstitution of brain myeloid cell and microglia upon transplantation of hematopoietic cells enriched in microglia reconstitution potential. The invention also provides compositions and methods for ablating and reconstituting microglia.
    Type: Grant
    Filed: October 16, 2017
    Date of Patent: April 16, 2024
    Assignees: CHILDREN'S MEDICAL CENTER CORPORATION, OSPEDALE SAN RAFFAELE S.R.L., POLITECNICO DI MILANO, FONDAZIONE TELETHON ETS, DANA-FARBER CANCER INSTITUTE, INC
    Inventors: Alessandra Biffi, Marco Peviani, Davide Moscatelli, Alessia Capotondo, Rita Milazzo, Umberto Capasso Palmiero
  • Publication number: 20240115693
    Abstract: Provided herein are nanoparticles which enhance the immunogenicity of antigens for use in Beta coronavirus (e.g., MERS-CoV, SARS-CoV-1, or SARS-CoV-2) vaccines, as well as immunogenic compositions comprising the antigen nanoparticles and additional adjuvants for further enhancing immunogenicity.
    Type: Application
    Filed: June 23, 2022
    Publication date: April 11, 2024
    Applicants: Children's Medical Center Corporation, Dana-Farber Cancer Institute, Inc.
    Inventors: Francesco Borriello, Ofer Levy, David J. Dowling, Sirano Dhe-Paganon, Hyuk-Soo Seo
  • Patent number: 11952432
    Abstract: The disclosure relates to cell-permeable stabilized peptide modules and methods of use for e.g., cellular delivery of cargoes.
    Type: Grant
    Filed: February 7, 2019
    Date of Patent: April 9, 2024
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Loren D. Walensky, Rida Mourtada, Henry D. Herce